Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1

Conditions

Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Uterine Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cisplatin 72Brachytherapy 31Radiotherapy 26Paclitaxel 23Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 21human papillomavirus vaccine, L1 type 16, 18 20Topotecan 18Papillomavirus Vaccines 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 16pembrolizumab 14Radiation 12Gemcitabine 12Early Intervention, Educational 12Colposcopy 12Methods 11Magnetic Resonance Spectroscopy 11atezolizumab 10Radiotherapy, Intensity-Modulated 10Blood Specimen Collection 10Papanicolaou Test 9Docetaxel 9Vaccines, Synthetic 8Platinum 8Nivolumab 8Ipilimumab 8Counseling 81,2-diaminocyclohexaneplatinum II citrate 8Vaccines 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Uterine Cervical Neoplasms × ferumoxtran-10 × Clear all
NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

University Health Network, Toronto

Phase 1/2 Completed
61 enrolled
GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

NCT00416455 2019-07-23

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
384 enrolled 23 charts
Gynecologic

Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡